VYNE - H.C. Wainwright raises VYNE Therapeutics target

VYNE Therapeutics (VYNE) is up 10% after H.C. Wainwright reiterated its Buy rating and boosted its price target on ZILXI's (minocycline) entry to U.S. pharmaceutical market.The firm raised its price target to $3.50 from $3, implying an approximately 17% upside. Analyst Oren Livnat says: Amzeeq growth is on track, and Zilxi is about to launch with "coverage out of the gate and dermatologists eager for better rosacea treatment."Previously: VYNE Therapeutics' Zilxi topical foam 1.5% is now available nationwide (Oct. 1)

For further details see:

H.C. Wainwright raises VYNE Therapeutics target